Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PAH Market Heats Up: New Approvals For Actelion, United Therapeutics

Executive Summary

With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015

You may also be interested in...



FDA's Warning On Postmarketing Adverse Event Reporting To Actelion Signals Enforcement Trend

While still much less frequent than GMP warning letters, PADE letters are on the rise, with FDA focusing on reports for drugs with known serious safety issues.

Lee's Pharmaceutical In-Licenses United Therapeutics' Pulmonary Arterial Hypertension Treatment Remodulin In China

SHANGHAI - Hong Kong-based Lee's Pharmaceutical and U.S.-based United Therapeutics signed an agreement for the distribution of United Therapeutics' pulmonary arterial hypertension treatment Remodulin (treprostinil) in China, despite a recent setback for the drug's launch in Europe

FDA Panel To Weigh REMS For Jazz's Fibromyalgia Candidate

Discussions on sodium oxybate likely to stray into effectiveness of current risk management measures for company's narcolepsy drug Xyrem, which contains the same active ingredient.

Related Content

Topics

UsernamePublicRestriction

Register

PS051389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel